View ValuationThis company is no longer activeThe company may no longer be operating, as it may be out of business. Find out why through their latest events.See Latest EventsARCA biopharma 将来の成長Future 基準チェック /06現在、 ARCA biopharmaの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Biotechs 収益成長25.3%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updates分析記事 • Apr 04Companies Like ARCA biopharma (NASDAQ:ABIO) Can Afford To Invest In GrowthEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...New Risk • Apr 04New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 26% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (26% average weekly change). Earnings have declined by 8.4% per year over the past 5 years. Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (US$47.1m market cap).お知らせ • Feb 09Arca Biopharma, Inc. Announces Executive ChangesARCA biopharma, Inc. announced on February 2, 2024, Raymond L. Woosley, M.D., Ph.D. and Dan Mitchell each resigned from the board of directors of the company, effective immediately. Upon the effectiveness of their resignations, Dr. Woosley and Mr. Mitchell each ceased to serve on any Board committees, including as Chairperson of the Nominating & Corporate Governance Committee and as member of the Compensation Committee, and as member of the Audit Committee and Nominating & Corporate Governance Committee, respectively. Each of Dr. Woosley’s and Mr. Mitchell’s resignation was not the result of any disagreement with ARCA on any matter relating to ARCA’s operations, policies or practices. In connection with Dr. Woosley’s and Mr. Mitchell’s resignations, the Board reduced the size of the Board from eight (8) to six (6) directors.お知らせ • Dec 20ARCA biopharma, Inc., Annual General Meeting, Jan 30, 2024ARCA biopharma, Inc., Annual General Meeting, Jan 30, 2024, at 09:00 US Mountain Standard Time. Location: Denver Marriott Westminster 7000 Church Ranch Blvd, Westminster, Colorado 80021 Colorado United States Agenda: To elect the Board of Directors’ nominees, Dr. Michael R. Bristow and Mr. Robert E. Conway, to the Board of Directors to hold office until the 2026 Annual Meeting of Stockholders; to ratify the selection by the Audit Committee of the Board of Directors of KPMG LLP as independent registered public accounting firm of the company for its fiscal year ending December 31, 2023; to approve, on an advisory basis, the compensation of the company’s named executive officers, as disclosed in this proxy statement; and to consider any other business that is properly brought before the meeting.お知らせ • Feb 15ARCA biopharma, Inc. Announces Departure of Christopher D. Ozeroff as Senior Vice President and General CounselARCA biopharma, Inc. and Christopher D. Ozeroff, the Secretary, Senior Vice President and General Counsel of ARCA have mutually agreed to conclude Mr. Ozeroff’s employment effective March 31, 2023. Mr. Ozeroff's departure is not the result of any disagreement with ARCA on any matter relating to its operations, policies or practices, or regarding the general direction of the company.Board Change • Nov 16Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 1 experienced director. 5 highly experienced directors. Director Jacob Ma-Weaver was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.分析記事 • Sep 24Is ARCA biopharma (NASDAQ:ABIO) In A Good Position To Deliver On Growth Plans?Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Seeking Alpha • May 03ARCA biopharma: Activist's Pressure Could Make This Into A Liquidation PlayActivist is pushing ARCA biopharma to stop new developments and return cash to shareholders. Subsequently, management has started a strategic review. The company's cash position (minus liabilities) stands at $3.19/share offering a potential 45% upside if things play out according to the activist's demands.Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 5 highly experienced directors. Independent Director Anders Hove was the last director to join the board, commencing their role in 2017. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.分析記事 • Mar 18Is ARCA biopharma (NASDAQ:ABIO) In A Good Position To Deliver On Growth Plans?We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...分析記事 • Nov 27Is ARCA biopharma (NASDAQ:ABIO) In A Good Position To Deliver On Growth Plans?There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Recent Insider Transactions • Nov 25Senior VP recently bought US$113k worth of stockOn the 22nd of November, Christopher Ozeroff bought around 50k shares on-market at roughly US$2.26 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought US$219k more in shares than they have sold in the last 12 months.分析記事 • Jul 15Here's Why We're Not Too Worried About ARCA biopharma's (NASDAQ:ABIO) Cash Burn SituationThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...Executive Departure • May 15Chief Accounting Officer & VP of Finance has left the companyOn the 10th of May, Brian Selby's tenure as Chief Accounting Officer & VP of Finance ended after 6.4 years in the role. We don't have any record of a personal shareholding under Brian's name. Brian is the only executive to leave the company over the last 12 months.分析記事 • Mar 30Here's Why We're Not Too Worried About ARCA biopharma's (NASDAQ:ABIO) Cash Burn SituationJust because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Is New 90 Day High Low • Mar 05New 90-day low: US$3.98The company is down 5.0% from its price of US$4.19 on 04 December 2020. The American market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 3.0% over the same period.Is New 90 Day High Low • Feb 09New 90-day high: US$4.93The company is up 27% from its price of US$3.87 on 10 November 2020. The American market is up 16% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 25% over the same period.Is New 90 Day High Low • Jan 14New 90-day high: US$4.55The company is up 6.0% from its price of US$4.29 on 15 October 2020. The American market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 16% over the same period.分析記事 • Dec 15We Think ARCA biopharma (NASDAQ:ABIO) Can Afford To Drive Business GrowthEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Is New 90 Day High Low • Nov 10New 90-day low: US$3.81The company is down 44% from its price of US$6.79 on 11 August 2020. The American market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 4.0% over the same period.Is New 90 Day High Low • Oct 24New 90-day low: US$4.03The company is down 42% from its price of US$6.91 on 24 July 2020. The American market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 1.0% over the same period.Is New 90 Day High Low • Sep 24New 90-day low: US$4.18The company is down 39% from its price of US$6.85 on 26 June 2020. The American market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 3.0% over the same period. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、ARCA biopharma は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測NasdaqCM:ABIO - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数6/30/2024N/A-7-7-7N/A3/31/2024N/A-6-5-5N/A12/31/2023N/A-5-5-5N/A9/30/2023N/A-5-5-5N/A6/30/2023N/A-6-6-6N/A3/31/2023N/A-8-8-8N/A12/31/2022N/A-10-11-11N/A9/30/2022N/A-14-14-14N/A6/30/2022N/A-17-17-17N/A3/31/2022N/A-18-18-18N/A12/31/2021N/A-19-19-19N/A9/30/2021N/A-19-17-17N/A6/30/2021N/A-16-14-14N/A3/31/2021N/A-13-11-11N/A12/31/2020N/A-10-8-8N/A9/30/2020N/A-6-6-6N/A6/30/2020N/A-5-5-5N/A3/31/2020N/A-5-5-5N/A12/31/2019N/A-5-5-5N/A9/30/2019N/A-6-5-5N/A6/30/2019N/A-6-6-6N/A3/31/2019N/A-7-7-7N/A12/31/2018N/A-8-8-8N/A9/30/2018N/A-11-11-11N/A6/30/2018N/A-13-13-13N/A3/31/2018N/A-17N/A-16N/A12/31/2017N/A-18N/A-17N/A9/30/2017N/A-19N/A-17N/A6/30/2017N/A-19N/A-17N/A3/31/2017N/A-17N/A-15N/A12/31/2016N/A-16N/A-15N/A9/30/2016N/A-15N/A-14N/A6/30/2016N/A-14N/A-12N/A3/31/2016N/A-12N/A-11N/A12/31/2015N/A-11N/A-11N/A9/30/2015N/A-11N/A-10N/A6/30/2015N/A-10N/A-9N/A3/31/2015N/A-10N/A-9N/A12/31/2014N/A-10N/A-9N/A9/30/2014N/A-10N/A-9N/A6/30/2014N/A-9N/A-9N/A3/31/2014N/A-10N/A-8N/A12/31/2013N/A-9N/A-5N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: ABIOの予測収益成長が 貯蓄率 ( 2.5% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: ABIOの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: ABIOの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: ABIOの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: ABIOの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: ABIOの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2024/08/29 02:16終値2024/08/29 00:00収益2024/06/30年間収益2023/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋ARCA biopharma, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Edward WooAscendiant Capital Markets LLC
分析記事 • Apr 04Companies Like ARCA biopharma (NASDAQ:ABIO) Can Afford To Invest In GrowthEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
New Risk • Apr 04New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 26% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (26% average weekly change). Earnings have declined by 8.4% per year over the past 5 years. Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (US$47.1m market cap).
お知らせ • Feb 09Arca Biopharma, Inc. Announces Executive ChangesARCA biopharma, Inc. announced on February 2, 2024, Raymond L. Woosley, M.D., Ph.D. and Dan Mitchell each resigned from the board of directors of the company, effective immediately. Upon the effectiveness of their resignations, Dr. Woosley and Mr. Mitchell each ceased to serve on any Board committees, including as Chairperson of the Nominating & Corporate Governance Committee and as member of the Compensation Committee, and as member of the Audit Committee and Nominating & Corporate Governance Committee, respectively. Each of Dr. Woosley’s and Mr. Mitchell’s resignation was not the result of any disagreement with ARCA on any matter relating to ARCA’s operations, policies or practices. In connection with Dr. Woosley’s and Mr. Mitchell’s resignations, the Board reduced the size of the Board from eight (8) to six (6) directors.
お知らせ • Dec 20ARCA biopharma, Inc., Annual General Meeting, Jan 30, 2024ARCA biopharma, Inc., Annual General Meeting, Jan 30, 2024, at 09:00 US Mountain Standard Time. Location: Denver Marriott Westminster 7000 Church Ranch Blvd, Westminster, Colorado 80021 Colorado United States Agenda: To elect the Board of Directors’ nominees, Dr. Michael R. Bristow and Mr. Robert E. Conway, to the Board of Directors to hold office until the 2026 Annual Meeting of Stockholders; to ratify the selection by the Audit Committee of the Board of Directors of KPMG LLP as independent registered public accounting firm of the company for its fiscal year ending December 31, 2023; to approve, on an advisory basis, the compensation of the company’s named executive officers, as disclosed in this proxy statement; and to consider any other business that is properly brought before the meeting.
お知らせ • Feb 15ARCA biopharma, Inc. Announces Departure of Christopher D. Ozeroff as Senior Vice President and General CounselARCA biopharma, Inc. and Christopher D. Ozeroff, the Secretary, Senior Vice President and General Counsel of ARCA have mutually agreed to conclude Mr. Ozeroff’s employment effective March 31, 2023. Mr. Ozeroff's departure is not the result of any disagreement with ARCA on any matter relating to its operations, policies or practices, or regarding the general direction of the company.
Board Change • Nov 16Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 1 experienced director. 5 highly experienced directors. Director Jacob Ma-Weaver was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
分析記事 • Sep 24Is ARCA biopharma (NASDAQ:ABIO) In A Good Position To Deliver On Growth Plans?Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • May 03ARCA biopharma: Activist's Pressure Could Make This Into A Liquidation PlayActivist is pushing ARCA biopharma to stop new developments and return cash to shareholders. Subsequently, management has started a strategic review. The company's cash position (minus liabilities) stands at $3.19/share offering a potential 45% upside if things play out according to the activist's demands.
Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 5 highly experienced directors. Independent Director Anders Hove was the last director to join the board, commencing their role in 2017. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
分析記事 • Mar 18Is ARCA biopharma (NASDAQ:ABIO) In A Good Position To Deliver On Growth Plans?We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
分析記事 • Nov 27Is ARCA biopharma (NASDAQ:ABIO) In A Good Position To Deliver On Growth Plans?There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Recent Insider Transactions • Nov 25Senior VP recently bought US$113k worth of stockOn the 22nd of November, Christopher Ozeroff bought around 50k shares on-market at roughly US$2.26 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought US$219k more in shares than they have sold in the last 12 months.
分析記事 • Jul 15Here's Why We're Not Too Worried About ARCA biopharma's (NASDAQ:ABIO) Cash Burn SituationThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Executive Departure • May 15Chief Accounting Officer & VP of Finance has left the companyOn the 10th of May, Brian Selby's tenure as Chief Accounting Officer & VP of Finance ended after 6.4 years in the role. We don't have any record of a personal shareholding under Brian's name. Brian is the only executive to leave the company over the last 12 months.
分析記事 • Mar 30Here's Why We're Not Too Worried About ARCA biopharma's (NASDAQ:ABIO) Cash Burn SituationJust because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Is New 90 Day High Low • Mar 05New 90-day low: US$3.98The company is down 5.0% from its price of US$4.19 on 04 December 2020. The American market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 3.0% over the same period.
Is New 90 Day High Low • Feb 09New 90-day high: US$4.93The company is up 27% from its price of US$3.87 on 10 November 2020. The American market is up 16% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 25% over the same period.
Is New 90 Day High Low • Jan 14New 90-day high: US$4.55The company is up 6.0% from its price of US$4.29 on 15 October 2020. The American market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 16% over the same period.
分析記事 • Dec 15We Think ARCA biopharma (NASDAQ:ABIO) Can Afford To Drive Business GrowthEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Is New 90 Day High Low • Nov 10New 90-day low: US$3.81The company is down 44% from its price of US$6.79 on 11 August 2020. The American market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 4.0% over the same period.
Is New 90 Day High Low • Oct 24New 90-day low: US$4.03The company is down 42% from its price of US$6.91 on 24 July 2020. The American market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 1.0% over the same period.
Is New 90 Day High Low • Sep 24New 90-day low: US$4.18The company is down 39% from its price of US$6.85 on 26 June 2020. The American market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 3.0% over the same period.